Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.44 |
| ▸ | FADS1 | O60427 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662606 | 0.89 | UTS2R (0.56) | UTS2RTRPA1KDM4EACHECDC7 | |
| SCHEMBL13996487 | 0.86 | UTS2R (0.50) | UTS2RTRPA1KDM4EACHEMAPK10 | |
| SCHEMBL3104864 | 0.83 | KDM4E (0.48) | TRPA1KDM4EACHEMAPK10FADS1 | |
| SCHEMBL10831138 | 0.82 | CDC7 (0.46) | UTS2RTRPA1KDM4ETSHRCDC7 | |
| SCHEMBL10831906 | 0.82 | GAA (0.51) | TRPA1ACHEADRA2AGAA | |
| SCHEMBL10367587 | 0.81 | GAA (0.55) | TSHRCDC7GAA | |
| SCHEMBL11087609 | 0.80 | TOP2A (0.52) | KDM4EADRA2AGAA | |
| SCHEMBL700943 | 0.79 | TRPA1 (0.50) | TRPA1KDM4EACHEMAPK10FADS1 | |
| SCHEMBL19505620 | 0.79 | TRPA1 (0.50) | TRPA1KDM4EACHEMAPK10FADS1 | |
| SCHEMBL10831655 | 0.78 | UTS2R (0.41) | UTS2RTRPA1ACHETSHRCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127333-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-1335907-B1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2010-06-09 | — | — | EP | disclosed |
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | disclosed |
| EP-1337518-B1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB PUBL (SE) | 2009-06-17 | — | — | EP | disclosed |
| CN-100484933-C | Novel pyrazine compounds, their use in preparing medicament for treating diseases correlated with serotonin | BIOVITRUM AB (SE) | 2009-05-06 | — | — | CN | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| CN-1329389-C | Novel compounds and their use | BIOVITRUM AB (SE) | 2007-08-01 | — | — | CN | disclosed |
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| EP-1337518-A1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1301476-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| US-20020103204-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-08-01 | — | — | US | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| WO-2002040457-A1 | PIPERAZINYLPYRAZINES COMPOUNDS AS ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103204-A1 | Novel compounds and their use | HTR2C, HTR1A, HTR1B | UTS2R 573/4885TRPA1 361/4885KDM4E 2610/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | UTS2R 1958/4885TRPA1 4456/4885KDM4E 1971/4885 |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | UTS2R 512/4885TRPA1 554/4885KDM4E 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.